Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
BRAF+
•
Langerhans Cell Histiocytosis
Do you recommend using cell-free BRAFV600E to track response to therapy in pediatric patients with langerhans cell histiocytosis?
Related Questions
What is your standard for monitoring triglyceride level during therapy for ALL, particularly in regards to receiving pegaspargase?
Is there any indication for IVIG in immunocompromised patients with only decreased IgM and/or IgA levels?
What screening tools or signs do you use to predict if a cancer patient is near end-of-life?
For what patients/diagnoses do you currently use sodium thiosulfate to reduce the risk of cisplatin associated ototoxicity?
How would you approach adjusting nivo+AVD therapy for advanced Hodgkin lymphoma if a patient develops treatment limited immunotherapy toxicity?
Can anti-cardiolipin or anti-beta-2 glycoprotein antibodies cause prolonged PTT in the absence of a lupus anticoagulant?
Is there any benefit of using aspirin to mitigate VTE risk in testosterone-induced polycythemia?
How do you approach revaccination after chemotherapy, and what labs (if any) do you use to assess immune reconstitution?
What is your diagnostic and treatment approach to pediatric patients with erythrocytosis?
At what point should surgical intervention be considered for vestibular schwannomas or other tumors in pediatric NF2 patients?
